Skip to content
DataLookout
Menu

SARCOGYNNCT07942168

Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

1-year progression-free survival (PFS)
Timeframe: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)

Secondary (3)

Overall Survival
Objective Response Rate
incidence of Adverse events

Arms and interventions

DoxorubicinActive comparator

Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days.

Doxorubicin+DacarbazineExperimental

Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days.

Drugs: Doxorubicin, dacarbazine

Sites

1 site in 1 country

  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)Moscow, Russia